Predictive performance of a vancomycin-aminoglycoside population model

Annals of Pharmacotherapy

Volumn 32, Issue 2, 1998, Pages 176-181

  Beringer, Paul M ^a   Wong Beringer, Annie ^b   Rho, Jay P ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Aminoglycosides; Concentrations; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG MONITORING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; PATIENT MONITORING; PRIORITY JOURNAL;

ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CALIFORNIA; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 0031893904     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17129     Document Type: Article

References (15)

1. Farber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23:138-41.
2. Sorrell T, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985;16:235-41.
3. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25:679-87.
4. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993;27:594-8.
5. Cantú TG, Yamanaka-Yuen NA, Leitman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994;18: 533-43.
6. Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there (editorial)? Clin Infect Dis 1994;18:544-6.
7. Ackerman BH. Clinical value of monitoring serum vancomycin concentrations (letter). Clin Infect Dis 1994;19:1180-1.
8. Wragge TM, Cooper BE. Correlation of aminoglycoside and vancomycin pharmacokinetic parameters. Ann Pharmacother 1993;27:1346-8.
9. Leonard AE, Boro MS. Vancomycin pharmacokinetics in middle-aged and elderly men. Am J Hosp Pharm 1994;51:798-800.
10. Hurst AK, Yoshinaga MA, Mitani GH, Foo KA, Jelliffe RW, Harrison EC. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother 1990;34:1165-71.
11. Jelliffe RW, Iglesias T, Hurst AK, Foo KA, Rodriguez J. Individualizing gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies. Clin Pharmacokinet 1991;21:461-78.
12. Jelliffe RW, Jelliffe SM. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex and weight. Math Biosci 1972;14:17-24.
13. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
14. Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosage regimens: one-versus two-compartment Bayesian models. Ther Drug Monit 1989;11:450-4.
15. Rodvold KA, Pryka RD, Garrison M, Rotschafer JC. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations. Ther Drug Monit 1989;11:269-75.